$TCRT
Alaunos Therapeutics, Inc.

2017 Q4 Form 10-Q Financial Statement

#000119312517334249 Filed on November 06, 2017

View on sec.gov

Income Statement

Concept 2017 Q4 2017 Q3 2016 Q3
Revenue $1.597M $1.598M $1.600M
YoY Change -0.19% -0.13% -14.44%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.850M $3.570M $3.540M
YoY Change 15.96% 0.85% 15.31%
% of Gross Profit
Research & Development $11.18M $11.11M $8.975M
YoY Change 19.06% 23.73% -47.11%
% of Gross Profit
Depreciation & Amortization $110.0K $90.00K $70.00K
YoY Change 83.33% 28.57% 16.67%
% of Gross Profit
Operating Expenses $15.03M $11.11M $8.975M
YoY Change 18.25% 23.73% -47.11%
Operating Profit -$13.44M -$13.08M -$10.91M
YoY Change 20.93% 19.83% -39.92%
Interest Expense $0.00 $200.0K $20.00K
YoY Change -100.0% 900.0%
% of Operating Profit
Other Income/Expense, Net $170.0K $175.0K $39.00K
YoY Change 466.67% 348.72% -1075.0%
Pretax Income -$13.27M -$12.70M -$10.85M
YoY Change 18.27% 17.05% -40.29%
Income Tax
% Of Pretax Income
Net Earnings -$18.27M -$17.60M -$14.45M
YoY Change 23.83% 21.87% -20.5%
Net Earnings / Revenue -1144.15% -1101.63% -902.81%
Basic Earnings Per Share
Diluted Earnings Per Share -$0.13 -$0.13 -$0.11
COMMON SHARES
Basic Shares Outstanding 142.0M shares 142.0M shares 131.7M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2017 Q4 2017 Q3 2016 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $70.90M $84.40M $94.70M
YoY Change -12.58% -10.88% -42.19%
Cash & Equivalents $70.95M $84.41M $94.68M
Short-Term Investments
Other Short-Term Assets $19.80M $30.50M $21.00M
YoY Change -16.81% 45.24% 153.01%
Inventory
Prepaid Expenses
Receivables $0.00 $0.00 $0.00
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $90.78M $114.9M $115.7M
YoY Change -13.44% -0.68% -32.93%
LONG-TERM ASSETS
Property, Plant & Equipment $1.211M $1.047M $825.0K
YoY Change 43.65% 26.91% 214.89%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $13.48M $496.0K $492.0K
YoY Change 2635.09% 0.81% 0.2%
Total Long-Term Assets $14.82M $1.671M $1.445M
YoY Change 912.5% 15.64% 64.02%
TOTAL ASSETS
Total Short-Term Assets $90.78M $114.9M $115.7M
Total Long-Term Assets $14.82M $1.671M $1.445M
Total Assets $105.6M $116.6M $117.1M
YoY Change -0.7% -0.48% -32.44%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.417M $1.524M $1.814M
YoY Change 2731.41% -15.99% -56.33%
Accrued Expenses $9.909M $10.11M $7.364M
YoY Change 8.78% 37.29% -59.4%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $20.86M $18.19M $15.74M
YoY Change 31.92% 15.53% -46.86%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $37.60M $39.10M $44.00M
YoY Change -11.53% -11.14% -11.82%
Total Long-Term Liabilities $37.60M $39.10M $44.00M
YoY Change -11.53% -11.14% -11.82%
TOTAL LIABILITIES
Total Short-Term Liabilities $20.86M $18.19M $15.74M
Total Long-Term Liabilities $37.60M $39.10M $44.00M
Total Liabilities $58.42M $57.29M $59.73M
YoY Change 0.16% -4.08% -24.89%
SHAREHOLDERS EQUITY
Retained Earnings -$712.4M -$699.2M -$646.8M
YoY Change 8.27% 8.1% 33.85%
Common Stock $615.6M $619.4M $582.4M
YoY Change 6.02% 6.36% 0.92%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$96.81M -$79.80M -$64.42M
YoY Change
Total Liabilities & Shareholders Equity $105.6M $116.6M $117.1M
YoY Change -0.7% -0.48% -32.44%

Cashflow Statement

Concept 2017 Q4 2017 Q3 2016 Q3
OPERATING ACTIVITIES
Net Income -$18.27M -$17.60M -$14.45M
YoY Change 23.83% 21.87% -20.5%
Depreciation, Depletion And Amortization $110.0K $90.00K $70.00K
YoY Change 83.33% 28.57% 16.67%
Cash From Operating Activities -$12.16M -$12.71M -$14.11M
YoY Change -6.96% -9.92% -131.22%
INVESTING ACTIVITIES
Capital Expenditures $280.0K $70.00K $210.0K
YoY Change 250.0% -66.67% 2000.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$280.0K -$70.00K -$210.0K
YoY Change 250.0% -66.67% 2000.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -1.030M 0.000 0.000
YoY Change 110.2% -100.0%
NET CHANGE
Cash From Operating Activities -12.16M -12.71M -14.11M
Cash From Investing Activities -280.0K -70.00K -210.0K
Cash From Financing Activities -1.030M 0.000 0.000
Net Change In Cash -13.47M -12.78M -14.32M
YoY Change -1.25% -10.75% -131.63%
FREE CASH FLOW
Cash From Operating Activities -$12.16M -$12.71M -$14.11M
Capital Expenditures $280.0K $70.00K $210.0K
Free Cash Flow -$12.44M -$12.78M -$14.32M
YoY Change -5.4% -10.75% -131.69%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2017Q2 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
4.893
CY2017Q2 ziop Public Offering Net Price Per Share
PublicOfferingNetPricePerShare
5.15
CY2017Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
141962789 shares
CY2017Q2 us-gaap Derivative Fair Value Of Derivative Liability
DerivativeFairValueOfDerivativeLiability
2480000
CY2016Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
94683000
CY2017Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000 shares
CY2017Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
141962789 shares
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
1540760 shares
CY2017Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2017Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
141962789 shares
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2696835 shares
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
4.62
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3622335 shares
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.14
CY2017Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2017Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
30000000 shares
CY2017Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-699169000
CY2017Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2017Q3 us-gaap Liabilities
Liabilities
57289000
CY2017Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
116559000
CY2017Q3 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
2350000
CY2017Q3 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
6389000
CY2017Q3 us-gaap Deferred Rent Credit
DeferredRentCredit
180000
CY2017Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1524000
CY2017Q3 us-gaap Stockholders Equity
StockholdersEquity
-79795000
CY2017Q3 us-gaap Derivative Fair Value Of Derivative Liability
DerivativeFairValueOfDerivativeLiability
2350000
CY2017Q3 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
36736000
CY2017Q3 us-gaap Common Stock Value
CommonStockValue
142000
CY2017Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
619232000
CY2017Q3 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
14000
CY2017Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2017Q3 us-gaap Liabilities Current
LiabilitiesCurrent
18189000
CY2017Q3 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
166000
CY2017Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
10110000
CY2017Q3 us-gaap Assets Current
AssetsCurrent
114888000
CY2017Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1047000
CY2017Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
5215000
CY2017Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
84406000
CY2017Q3 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
128000
CY2017Q3 us-gaap Receivables Net Current
ReceivablesNetCurrent
13000
CY2017Q3 us-gaap Assets
Assets
116559000
CY2017Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
496000
CY2017Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
30469000
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
5657000
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
140717000
CY2016Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000 shares
CY2016Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
132376670 shares
CY2016Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2016Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
132376670 shares
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2671835 shares
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
4.40
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3465335 shares
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.07
CY2016Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
dei Document Type
DocumentType
10-Q
dei Entity Central Index Key
EntityCentralIndexKey
0001107421
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-42513000
CY2016Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
30000000 shares
CY2016Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-657997000
CY2016Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2016Q4 us-gaap Liabilities
Liabilities
58325000
CY2016Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
106348000
CY2016Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
862000
CY2016Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
6389000
CY2016Q4 us-gaap Deferred Rent Credit
DeferredRentCredit
281000
CY2016Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
156000
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
-77298000
CY2016Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
41528000
CY2016Q4 us-gaap Common Stock Value
CommonStockValue
132000
CY2016Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
580567000
CY2016Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
126000
CY2016Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2016Q4 us-gaap Liabilities Current
LiabilitiesCurrent
15809000
CY2016Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
155000
CY2016Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
9109000
CY2016Q4 us-gaap Assets Current
AssetsCurrent
104884000
CY2016Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
843000
CY2016Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
3383000
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
81053000
CY2016Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
128000
CY2016Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
21000
CY2016Q4 us-gaap Assets
Assets
106348000
CY2016Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
493000
CY2016Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
23810000
CY2017Q2 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
9708738 shares
CY2017Q2 us-gaap Sale Of Stock Consideration Received On Transaction
SaleOfStockConsiderationReceivedOnTransaction
47300000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
27351409 shares
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2017
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y2M19D
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
4.85
dei Trading Symbol
TradingSymbol
ZIOP
dei Amendment Flag
AmendmentFlag
false
us-gaap Research And Development Arrangement Contract To Perform For Others Description And Terms
ResearchAndDevelopmentArrangementContractToPerformForOthersDescriptionAndTerms
Pursuant to the Research and Development Agreement, the Company, Intrexon and MD Anderson have agreed to form a joint steering committee that will oversee and manage the new and ongoing research programs. As provided under the MD Anderson License, the Company will provide funding for research and development activities in support of the research programs under the Research and Development Agreement for a period of three years and in an amount of no less than $15.0 million and no greater than $20.0 million per year.
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
6.64
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
6.28
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y4M20D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
122000 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.34
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
135689364 shares
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Period End Date
DocumentPeriodEndDate
2017-09-30
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
359000 shares
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
80000 shares
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.41
dei Entity Registrant Name
EntityRegistrantName
ZIOPHARM ONCOLOGY INC
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
859000 shares
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
461000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
3000
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-1292000
us-gaap Contracts Revenue
ContractsRevenue
4792000
us-gaap Operating Income Loss
OperatingIncomeLoss
-40057000
us-gaap Net Income Loss
NetIncomeLoss
-41050000
us-gaap Interest Paid
InterestPaid
0
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6165000
us-gaap Payments For Repurchase Of Equity
PaymentsForRepurchaseOfEquity
1042000
us-gaap Income Taxes Paid
IncomeTaxesPaid
0
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
99000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
47270000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
299000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-54989000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
6660000
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-8000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1368000
us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
-102000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-461000
us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
13939000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
47270000
us-gaap Share Based Compensation
ShareBasedCompensation
6165000
us-gaap Stock Redeemed Or Called During Period Value
StockRedeemedOrCalledDuringPeriodValue
1042000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
259000
us-gaap Dividends Preferred Stock
DividendsPreferredStock
13939000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-4792000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10946000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1002000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
46327000
us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
44849000
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
545000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
33903000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
3353000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
99000
ziop Common Stock Issuance Cost
CommonStockIssuanceCost
2700000
ziop Change In Research And Development Expenses
ChangeInResearchAndDevelopmentExpenses
6200000
ziop Research And Development Service Agreement Quarterly Payment
ResearchAndDevelopmentServiceAgreementQuarterlyPayment
9300000
ziop Research And Development Service Agreement Aggregate Payment
ResearchAndDevelopmentServiceAgreementAggregatePayment
35600000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
27249143 shares
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-45261000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
5.36
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
130347370 shares
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.21
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
157300 shares
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
469000
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
2000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-1000
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
21000
us-gaap Contracts Revenue
ContractsRevenue
5264000
us-gaap Operating Income Loss
OperatingIncomeLoss
-154196000
us-gaap Net Income Loss
NetIncomeLoss
-154073000
us-gaap Interest Paid
InterestPaid
0
us-gaap Payments For Repurchase Of Equity
PaymentsForRepurchaseOfEquity
853000
us-gaap Income Taxes Paid
IncomeTaxesPaid
0
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
102000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-157664000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
9611000
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-421000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-194000
us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
-322000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-469000
us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
3591000
us-gaap Share Based Compensation
ShareBasedCompensation
6094000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
227000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-5264000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11058000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1542000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
-304000
us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
159460000
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
231000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
148402000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-46034000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
551000
ziop Issuance Of Common Stock In Connection With License Agreement
IssuanceOfCommonStockInConnectionWithLicenseAgreement
87000
ziop Issuance Of Preferred Stock In Connection With License Agreement
IssuanceOfPreferredStockInConnectionWithLicenseAgreement
118936000
ziop Research And Development Service Agreement Quarterly Payment
ResearchAndDevelopmentServiceAgreementQuarterlyPayment
11300000
CY2016 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y10M17D
CY2016Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.7934 pure
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00 pure
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.7926 pure
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0127 pure
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.71
CY2016Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
130496035 shares
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0137 pure
CY2016Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.11
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
21300 shares
CY2016Q3 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
21000
CY2016Q3 us-gaap Contracts Revenue
ContractsRevenue
1598000
CY2016Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-10914000
CY2016Q3 us-gaap Net Income Loss
NetIncomeLoss
-10854000
CY2016Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
39000
CY2016Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-14445000
CY2016Q3 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
3591000
CY2016Q3 us-gaap Share Based Compensation
ShareBasedCompensation
2019000
CY2016Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3537000
CY2016Q3 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
12512000
CY2016Q3 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
109000
CY2016Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8975000
CY2017Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.8095 pure
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00 pure
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.8082 pure
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0188 pure
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.29
CY2017Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
140632297 shares
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0201 pure
CY2017Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.13
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
593500 shares
CY2017Q3 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
202000
CY2017Q3 us-gaap Contracts Revenue
ContractsRevenue
1598000
CY2017Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-13078000
CY2017Q3 us-gaap Net Income Loss
NetIncomeLoss
-12701000
CY2017Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
175000
CY2017Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-17604000
CY2017Q3 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
4903000
CY2017Q3 us-gaap Share Based Compensation
ShareBasedCompensation
2082000
CY2017Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3571000
CY2017Q3 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
14676000
CY2017Q3 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
177000
CY2017Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11105000
CY2017Q3 ziop Embedded Derivative Dividend Amount
EmbeddedDerivativeDividendAmount
72000

Files In Submission

Name View Source Status
0001193125-17-334249-index-headers.html Edgar Link pending
0001193125-17-334249-index.html Edgar Link pending
0001193125-17-334249.txt Edgar Link pending
0001193125-17-334249-xbrl.zip Edgar Link pending
d464223d10q.htm Edgar Link pending
d464223dex311.htm Edgar Link pending
d464223dex312.htm Edgar Link pending
d464223dex321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g464223dsp38a.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
ziop-20170930.xml Edgar Link completed
ziop-20170930.xsd Edgar Link pending
ziop-20170930_cal.xml Edgar Link unprocessable
ziop-20170930_def.xml Edgar Link unprocessable
ziop-20170930_lab.xml Edgar Link unprocessable
ziop-20170930_pre.xml Edgar Link unprocessable